Sarcopenia and myosteatosis in patients undergoing curative radiotherapy for head and neck cancer: Impact on survival, treatment completion, hospital admission and cost
- 1 July 2020
- journal article
- research article
- Published by Wiley in Journal of Human Nutrition and Dietetics
- Vol. 33 (6) , 811-821
Abstract
Background: Computed tomography (CT) is the gold standard of body composition analysis at the tissue‐organ level. The present study aimed to determine the impact of CT‐defined sarcopenia and myosteatosis on outcomes, including overall survival, unplanned hospital admissions and related costs, in patients who had completed treatment of curative intent for head and neck cancer (HNC).Methods: Retrospective observational study of patients undergoing radiotherapy of curative intent ± other treatment modalities for HNC. Tissue density data derived at the third lumbar vertebra (L3) were evaluated with sarcopenia defined per sex‐specific published threshold values for skeletal muscle index, stratified by body mass index and mean skeletal muscle attenuation in HU (Hounsfield units).Results: Pre‐ or post‐treatment images were available for 79/98 patients (80.6%) and 61/98 patients (62.2%), respectively. Sarcopenia was present in 42/79 patients pre‐treatment and 36/61 patients post‐treatment, whereas myosteatosis was present in 63/79 patients pre‐treatment and 48/61 patients post‐treatment. In patients with pre‐ and post‐treatment images (n = 60), the median (range) percentage weight change was −8.5% (−29.9 to +11.7). On multivariable analysis, a post‐treatment sarcopenia hazard ratio of 3.87 (95% confidence interval = 1.22–12.24, P = 0.021) and a pre‐treatment myosteatosis hazard ratio of 8.86 (95% confidence interval = 1.12–69.88, P = 0.038) were independent predictors of reduced overall survival. There was no difference in radiotherapy or chemotherapy treatment completion based on pre‐treatment sarcopenia status. The mean (SD) difference unplanned hospital admission cost was $15 846 ($17 707) for patients without sarcopenia versus $47 945 ($82 688) for patients with sarcopenia at any time point (P = 0.077).Conclusions: As CT‐defined sarcopenia and myosteatosis hold clinically meaningful prognostic value, muscle status evaluation is recommended in routine clinical practice.Keywords
Funding Information
- Sydney Research
This publication has 39 references indexed in Scilit:
- Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomesSeminars in Cell & Developmental Biology, 2016
- Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopeniaProceedings of the Nutrition Society, 2015
- Lean Tissue ImagingJournal of Parenteral and Enteral Nutrition, 2014
- Obesity paradox in cancer: new insights provided by body compositionThe American Journal of Clinical Nutrition, 2014
- Measurement of skeletal muscle radiation attenuation and basis of its biological variationActa Physiologica, 2014
- Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass IndexJournal of Clinical Oncology, 2013
- Sarcopenia: European consensus on definition and diagnosisAge and Ageing, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional imageJournal of Applied Physiology, 2004